DAX24.841 -0,1%Est506.001 -0,2%MSCI World4.343 -0,1%Top 10 Crypto8,5800 +1,9%Nas22.597 -2,0%Bitcoin56.307 +1,0%Euro1,1861 -0,1%Öl67,66 +0,2%Gold4.967 +0,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens 723610 Deutsche Telekom 555750 Siemens Energy ENER6Y SAP 716460 Rheinmetall 703000 Mercedes-Benz Group (ex Daimler) 710000 NVIDIA 918422 Amazon 906866 BASF BASF11 Lufthansa 823212 Microsoft 870747 Bayer BAY001 Allianz 840400 DroneShield A2DMAA Gerresheimer A0LD6E
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Vor US-Inflationsdaten: DAX wenig bewegt -- Asiens Börsen schließen rot -- Coinbase-Umsatz enttäuscht -- Delivery Hero von Talabat belastet -- Rivian, Applied Materials, Adyen, Apple, Arista im Fokus
Top News
Klöckner-&-Co-Aktie unverändert: Aufsichtsrat unterstützt Übernahme durch Worthington Klöckner-&-Co-Aktie unverändert: Aufsichtsrat unterstützt Übernahme durch Worthington
Leclanché-Aktie im Blick: Finanzielle Turbulenzen - Liquiditätsengpässe verzögern Gehaltszahlungen Leclanché-Aktie im Blick: Finanzielle Turbulenzen - Liquiditätsengpässe verzögern Gehaltszahlungen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

REGENXBIO Aktie

Kaufen
Verkaufen
REGENXBIO Aktien-Sparplan
6,90 EUR -0,10 EUR -1,43 %
STU
8,34 USD -0,14 USD -1,65 %
BTT
REGENXBIO jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.362,84 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA140E0

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75901B1070

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRGNX

REGENXBIO Aktien News

DatumMeistgelesen
PR NewswireREGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
PR NewswireREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
PR NewswireREGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
PR NewswireREGENXBIO Appoints Mitchell Chan as Chief Financial Officer
PR NewswireREGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
PR NewswireREGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
PR NewswireREGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
PR NewswireREGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
PR NewswireREGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
PR NewswireREGENXBIO Announces Leadership Transition
PR NewswireREGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PR NewswireREGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
PR NewswireREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
PR NewswireREGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
PR NewswireREGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
PR NewswireREGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
PR NewswireREGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
PR NewswireREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
PR NewswireREGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
PR NewswireREGENXBIO to Participate in the Jefferies CNS/Neuro Summit
PR NewswireREGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

REGENXBIO News

REGENXBIO News: auf dieser Seite finden Sie alle REGENXBIO News und Nachrichten zur REGENXBIO Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch REGENXBIO News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um REGENXBIO News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.